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Abstract
Background: Methicillin-resistant S. aureus (MRSA) with low susceptibility to glycopeptides is
uncommon.
Case presentation: The case of a 50-year-old non-drug addict patient presenting with tricuspid
valve infective endocarditis (IE) by MRSA resistant to vancomycin and linezolid is presented. There
was response only to quinupristin/dalfopristin. He had a motorcycling accident four years before
undergoing right above-the-knee amputation and orthopaedic fixation of the left limb. There were
multiple episodes of left MRSA-osteomyelitis controlled after surgery and vancomycin therapy.
MRSA isolated from the blood at the time of IE presented with the same profile than the isolated
four years earlier. Sequential treatment with teicoplanin-cotrimoxazole and Linezolid associated to
vancomycin – rifampicin – cotrimoxazole had no improvement. Infection was controlled after 28
days of therapy with quinupristin/dalfopristin.
Conclusion: The literature presents only a few cases of MRSA IE not susceptible to glycopeptides
in not drug addicted patients. This case shows the comparison of a highly-resistant MRSA after
previous  S. aureus osteomyelitis treated with glycopeptides. This is the first description of
successful treatment of resistant-MRSA IE of the tricuspid valve complicated by multiple pulmonary
septic infarction with quinupristin/dalfopristin
Background
Infective endocarditis was an invariably fatal infection
before the availability of antimicrobials. A significant per-
centage of patients still succumb to it despite aggressive
treatment especially when infected with virulent organ-
isms such as Staphylococcus aureus. Overall, approximately
20% of S. aureus isolates in Europe are reported as methi-
cillin-resistant, whereas in US hospitals the prevalence
ranges from 33% to 55%. The past few years have also wit-
nessed an increase in life-threatening community-
acquired infections caused by MRSA. Most infections with
VISA (vancomycin-intermediate S. aureus) and VRSA
(vancomycin-resistant S. aureus) have occurred in a set-
ting of heavy prior use of glycopeptides and other antimi-
crobial agents. Emergence of reduced vancomycin
susceptibility and clinical resistance in S. aureus increases
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the possibility that currently available antimicrobial
agents may become ineffective for treating systemic infec-
tions.
Case presentation
A 50 year-old non-insulin dependant diabetic male was
admitted with the chief complaints of three-day fever and
poor general status. He had a 3/6 diastolic murmur over
the xyphoid process. Chest X-ray did not show abnormal-
ities. Abdominal ultrasound showed splenomegaly. His
past history included the following: In June 2000 he had
a road traffic accident resulting in multiple trauma, requir-
ing right above-the-knee amputation and orthopaedic fix-
ation of the left lower limb. He later presented with
multiple episodes of osteomyelitis of this limb treated
with iv. antibiotics. Prosthetic shafts were removed in
June 2002 and MRSA isolated. Three months later he pre-
sented with a spontaneous fracture of the limb and
required new surgical fixation due to infectious pseudoar-
throsis. MRSA was isolated again. In October 2003 he was
re-operated and underwent auto-transplantation of corti-
cospongiosa. During these episodes he was given teico-
planin, cotrimoxazole, rifampicin, tetracycline and
quinolones at intervals of 7 to 20 days at another institu-
tion in a distant site. Table 1 shows the summary of the
multiple events.
In June 2004 he was admitted to our institution with the
above mentioned complaints. Transthoracic echocardiog-
raphy (TTE) showed a large vegetation (size 2.5 × 0.8 cm)
on the anterior leaflet of the tricuspid valve (Figure 1) and
severe valve insufficiency, with a normal left ventricular
ejection fraction. Transesophageal echocardiography
(TEE) disclosed other pathologic findings. A total body
computed tomography scan was performed showing mul-
tiple bilateral areas suggesting pulmonary infarction (Fig-
ure 2). A labelled leucocyte scintigraphy didn't reveal any
specific infective localization.
The patient was treated with an association of oxacillin 16
gr/day and gentamycin 240 mg/day that was shifted two
days later to teicoplanin (1200 mg/12 h/IV) for the first 3
days followed with 1200 mg/day/IV) and cotrimoxazole
(480 mg/12 h/IV) as MRSA was isolated. The MRSA was
resistant to clindamycin (MIC>8 mcg/ml), erythromycin
(MIC>8 mcg/ml), gentamycin (MIC>16 mcg/ml), nor-
floxacin (MIC>16 mcg/ml), ofloxacin (MIC>8 mcg/ml),
oxacillin (MIC>4 mcg/ml), penicillin (MIC>0.8 mcg/ml),
and tobramycin (MIC>16 mcg/ml). The MRSA resulted
susceptible to rifampicin (MIC<0.5 mcg/ml), teicoplanin
(MIC<0.5 mcg/ml), tetracicline (MIC<1 mcg/ml), cotri-
moxazole (MIC<10 mcg/ml) and vancomycin (MIC<1
mcg/ml). Linezolid 600 mg daily iv was started 8 days
later because of worsening condition (Linezolid was not
tested in-vitro). However this proved to be ineffective as
the patient still presented fever and positive blood cul-
tures for MRSA maintaining the same strains. A new TTE
was performed showing the presence of a new vegetation
on the anterior leaflet of the tricuspid valve.
Table 1: Summary of multiple events
Period Hospital 
Admission
Cause Isolated 
pathogen
Antibiotic therapy
June 2000 ICU Road Traffic accident - -
August 2000 – 
December 2000
Rehabilitation Unit Rehabilitation, Orthopaedic 
fixation, osteomyelitis left 
leg
- Ciprofloxacin 500 mg/12 h/21 days
Amoxicillin/clavulanic acid 1 g/12 h/28 days
June 2002 Orthopaedic Unit Re-Orthopaedic fixation MRSA Minocycline 100 mg/12 h/14 days
Cotrimoxazole 480 mg./12 h/8 days
Teicoplanin 200 mg/24 h/8 days
September 2002 Orthopaedic Unit Spontaneous limb fracture 
– Orthopaedic fixation
MRSA Teicoplanin 400 mg/24 h/8 days
Rifampicin 600 mg/12 h/10 days
February 2003 – 
May 2003
Rehabilitation Unit Rehabilitation - -
October 2003 Orthopaedic Unit Autotransplantation of 
corticospongiosa
MRSA Ciprofloxacin 500/12 h/14 days
Teicoplanin 200 mg/24 h/8 days
June 2004 – 
August 2004
Internal Medicine 
Unit and Cardiac 
Surgery Unit
Tricuspid valve endocarditis MRSA Cefixime 800 mg/2 days
Oxacillin 16 g/24 h/3 days + Gentamycin 240 mg/24 h/3 
days
Teicoplanin 1200 mg/24 h/8 days + Cotrimoxazole 960 
mg/24 h/8 days
Linezolid 600 mg/24 h/7 days
Vancomycin 3 g/24 h/12 days + Rifampicin 600 mg/24 h/
12 days+ Cotrimoxazole 1440 mg/24 h/12 days
Quinupristin/dalfopristin 750 mg/8 h/36 daysBMC Infectious Diseases 2006, 6:124 http://www.biomedcentral.com/1471-2334/6/124
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Linezolid was then replaced with vancomycin (500 mg/6
h/IV), rifampicin (600 mg/8 h/IV) and cotrimoxazole
(480 mg/8 h/IV) that was again ineffective and after 12
days of therapy was suspended. After 27 days of ineffective
therapy the patient condition was very poor; TTE showed
new vegetations on the posterior leaflet of the tricuspid
valve with severe insufficiency and large pulmonary inf-
arctions. Quinupristin/dalfopristin were at 7.5 mg-Kg/8
h/IV. After three days of therapy the patient became afe-
brile and his condition improved. After 25 days of therapy
with quinupristin/dalfopristin, biological markers for
infection became normal and the patient underwent left
above-the-knee amputation as prevention treatment for
new infections. The therapy with quinupristin/dalfopris-
tin was suspended after 42 days. A Transesophageal
echocardiography and a thoracic computed tomography
scan were performed at the end of antibiotic therapy and
at 18 months after discharge showed complete regression
of the tricuspid vegetation, only mild valve insufficiency
and absence of residual pulmonary infarction.
Infective endocarditis is an uncommon disease. A recent
publication has shown that the incidence of IE is about 31
cases per million inhabitants. Right-sided IE represents
10% of all cases with tricuspid valve involvement in 90%
of cases. Moss and Munt showed the right-sided IE is more
frequent in drug-addicts (63%) [2,3]. We present a case of
tricuspid IE complicated by multiple pulmonary septic
CT scan showing multiple areas of pulmonary infarction Figure 2
CT scan showing multiple areas of pulmonary infarction.
Transthoracic echocardiogram showing a vegetation on the septal leaflet of the tricuspid valve Figure 1
Transthoracic echocardiogram showing a vegetation on the septal leaflet of the tricuspid valve.Publish with BioMed Central    and   every 
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infarctions originated probably from a focus of chronic
osteomyelitis. The interesting aspect of this case is not
only the acute clinic presentation but also the high grade
of clinical resistance to the different antibiotic regimens
used [4]. The patient did not respond to the use of glyco-
peptides, teicoplanin and vancomycin always in associa-
tion with other drugs despite the positive in vitro
susceptibility to these antibiotics [5]. The use of linezolid
[6], a wide spectrum antibiotic, with a very good reported
action on the lungs [7] resulted ineffective with a concom-
itant dramatic deterioration of the clinical condition of
the patient. The use of quinupristin/dalfopristin [8] as sal-
vage therapy resulted in a very quick improvement after
three days and resulted in complete cure of tricuspid valve
IE and septic embolic lung abscesses. The antibiotic ther-
apy was continued for four weeks as recommended by the
American Heart Association guidelines [9] for compli-
cated right-sided endocarditis diminishing the rate of
relapses due. The decision to perform a left above-the-
knee amputation was considered as the only possible
guarantee of removal of chronic osteomyelitis focus and
was performed with the patient on quinupristin/dalfo-
pristin antibiotic treatment.
Conclusion
In this paper, we firstly reported a non-operated patient
with tricuspid valve endocarditis by MRSA complicated by
multiple pulmonary septic infarction cured with quinu-
pristin/dalfopristin. The use of these antibiotic agents
opens new perspectives in the management of severely ill
patients with invasive valve endocarditis infection.
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